Page 6 - Gland Pharma

Gland Pharma IPO: Expensive at a price tag of 30x the FY20 earnings

While prospects remain strong led by niche products and a differentiated business model, relatively rich valuations leave limited scope for upside in near-term

Gland Pharma's Rs 6,480-crore IPO gets 4% subscription on first day

On Friday, the company had allotted Rs 1,944 crore worth of shares to anchor investors

Street signs: Gland's grey market premium shrinks, banking stocks, and more

The grey market premium for Gland Pharma has come off sharply from Rs 185 per share to just Rs 60 per share

India's largest pharma IPO worth Rs 6,500 cr set to hit market next week

Fosun-owned Gland Pharma sets price band for its IPO at Rs 1,490-1,500 per share

Gland Pharma IPO price band at Rs 1,490-1,500, offer opens on Nov 9

Gland Pharma, which announced itsabout Rs 6,500 crore IPO, has set a price band of Rs 1,490-1,500 per share (face value of Rs one) and the issue will be open on November 9, an official said

Gland Pharma receives Sebi's go-ahead to launch IPO pegged at Rs 5,000 cr

Apart from the fresh issue, there is an offer for sale (OFS) of a little over 34 million shares as part of the IPO

China's Fosun International to consider $500 million IPO of Gland Pharma

Hyderabad-based Gland, founded in 1978, specializes in injectable drugs such as antibiotics, oncology and cardiology treatments

Govt plans to block $1.3-bn Gland Pharma-Fosun deal

The deal was announced last July when Shanghai Fosun agreed to buy an 86% stake in Gland Pharma

Fosun to buy KKR-backed Indian drugmaker for $1.4 bn: source

Target firm Gland Pharma makes a variety of injectables, which are harder to make than regular medicines